Cybin Inc.

$CYBN, a biopharmaceutical company focused on psychedelic based therapy for mental health conditions, had a nice run up in the latter part of September and is holding up pretty well after a small pullback. A big reason for the rise was news a couple weeks ago that Steve Cohen’s hedge fund Point72 Asset Management purchased almost 19 million shares

Share This Article

 

About the Author

Cybin Inc.

Joey Ramson